MIMETAS B.V.

Company Snapshot

Founded: 2013
Entity Type: Private
Employees: 100
Region: The Netherlands
Headquarter: Oegstgeest, The Netherlands
Key Geographics: The Netherlands, U.S., Japan
Corporate Address: Biopartner Building 5, De Limes 7, 2342 DH Oegstgeest The Netherlands Tel. +31-0-85-888-31-61 www.mimetas.com

Company Overview

Mimetas B.V. is a privately owned biotech company incorporated in 2013 and based in Leiden, Netherlands. In Leiden it performs most of its biological model development work, as well as development of novel hardware and assays. The manufacturing site, in Enschede, Netherlands, is where the company produces OrganoPlates. In Rockville, Md., the daughter company Mimetas Inc. is involved with selected R&D and business development activities inside the U.S.

Mimetas develops organ-on-a-chip models to specification in OrganoPlates and performs self-funded R&D on organ-on-a-chip models.

OrganoPlates are microfluidic 3D culture plates supporting up to 96 tissue models on a single plate. OrganoPlates contain Phaseguides, a proprietary, passive liquid handling technology for membrane-free definition of tissues in microfluidic chambers. OrganoPlates are based on the industry-standard 384-well plate for full compatibility with liquid handling and readout equipment. Within the plate, cells are contained in a gel, supporting 3D tissue configurations and cell-cell interactions. A continuous perfusion of media through the plate mimics blood flux and exchange of nutrients, oxygen and metabolites. The plates are versatile, supporting chemical gradients and coculture conditions. In this way, complex tissue models can be implemented in a straightforward way. 

MIMETAS B.V. In Reports

Organ-on-a-Chip: Global Markets

BCC Research Report: Dive into organ on a chip market report includes global revenue for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets

BCC Research Market Analyst says global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029.

3D Cell Cultures: Technologies and Global Markets

BCC Research Market Analyst says global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028 at a CAGR of 26.5% from 2023 through 2028.

Company's Business Segments

  • Products : The company generates revenue through products such as OrganoReady, Instruments, Workshops and Trainings, OrganoStart Packages.

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals
  • Life Sciences
AI Sentiment